Seastar Medical Holding Corp

This proposal asks shareholders to approve an amendment and restatement of the Company’s 2022 Omnibus Incentive Plan to increase the share reserve by 689,500 shares (from 207,046 to 896,546). Management seeks approval to preserve its primary tool for long‑term compensation—stock options, RSUs and other equity awards—which it argues are necessary to attract, motivate and retain employees, directors and consultants in a competitive biopharma labor market and to align employee incentives with shareholder value creation. The company frames the increase as meeting Nasdaq listing requirements, enabling incentive stock options to comply with Internal Revenue Code rules, and conforming to good corporate governance. The filing discloses that only ≈26,000 shares remained available as of March 31, 2026, making the requested increase material to allow future grants; this context explains the size and timing of the request. The Board acknowledges dilution risk and commits to managing burn rate and monitoring awards, but stockholders should evaluate the incremental dilution (689,500 shares) relative to current outstanding shares and historical grant practices. The proposal has governance implications because it grants the Compensation Committee broad discretion (including share counting, repricing limits requiring shareholder approval, and change‑in‑control provisions) that could affect executive compensation, succession incentives, and post‑control accelerations. From an investor perspective, the near‑term economic impact depends on pacing of grants and potential future financings; the company’s justification centers on retention and meeting technical exchange and tax requirements rather than an immediate operational need. The Board’s unanimous recommendation and stated rationale reduce procedural uncertainty, but shareholders may request clarity on expected grant pacing, dilution modeling, and specific limits on executive award concentration before consenting.

The adjournment proposal asks shareholders to grant the Board authority to postpone or adjourn the Annual Meeting if one or more proposals lack sufficient votes, effectively providing management additional time to solicit proxies and reach required approvals. Management seeks this approval as a procedural safeguard to avoid the need to reconvene at a later date without authority and to reduce the risk that necessary corporate actions cannot be taken due to broker non‑votes or shortfalls in support. The proposal has minimal substantive policy implications—its main effect is logistical and procedural—but it leverages the practical realities of broker voting rules where non‑routine matters (like the stock plan amendment) typically cannot be voted by brokers without instructions. For investors, the vote preserves the Board’s flexibility to extend campaigning for proposals, but it also enables management to continue seeking votes rather than immediately accepting a failed outcome; this could impose additional solicitation costs and delay corporate decision‑making. The Company frames the request as narrowly tailored (only to be used if needed for Proposals 1–3), and the Board’s unanimous recommendation signals predictable use only in contingencies; however, shareholders should be aware that repeated adjournments can defer outcomes and concentrate leverage for shareholders who continue to engage. Ultimately, the adjournment measure is a common procedural item designed to protect stockholder voting interests and the Company’s ability to obtain required approvals in light of broker voting limitations.